Kamada’s rabies treatment clears Phase III with an FDA app on deck

Damian Garde

Kamada's immunoglobulin for met its main goal in a late-stage trial, clearing the way for an FDA application next year.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS